Crysvita 20 mg (Burosumab SOLUTION) 20 MG

CRYSVITA 20 MG is a subcutaneous solution containing burosumab, used to manage certain metabolic conditions. This medication is designed to help regulate phosphate levels in the body.

Strength

20 MG

Manufacturer / TM Owner

KYOWA KIRIN, INC.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CRYSVITA 20 MG is primarily used to treat conditions related to phosphate metabolism. It is often prescribed for individuals with X-linked hypophosphatemia, a genetic disorder that affects phosphate levels in the body. This medication works by binding to a specific protein that regulates phosphate levels, helping to maintain balance. People often ask, 'What is CRYSVITA used for?' and the answer lies in its ability to manage phosphate-related disorders.

Side Effects

Common effects of CRYSVITA 20 MG may include injection site reactions, such as redness, swelling, or itching. Some individuals might experience headaches, joint pain, or fatigue. These effects are generally mild and temporary, but it's important to monitor any persistent or severe reactions.

Precautions & Warnings

CRYSVITA 20 MG should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Store the medication as directed, typically in a refrigerator, to maintain its efficacy. Always check the solution for particles or discoloration before use.

Avoid Interactions

CRYSVITA 20 MG may interact with other medications, including those that affect phosphate levels or bone metabolism. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of this medication.

References

Frequently Asked Questions

CRYSVITA is used to manage conditions related to phosphate metabolism, such as X-linked hypophosphatemia.

CRYSVITA is administered subcutaneously, typically by injection.

Common side effects include injection site reactions, headaches, joint pain, and fatigue.

It is important to consult a healthcare provider before combining CRYSVITA with other medications to avoid potential interactions.

CRYSVITA should be stored in a refrigerator to maintain its efficacy.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.